Heart failure: Epidemiollogy and prevention in India

National Medical Journal of India

Volumn 23, Issue 5, 2010, Pages 283-288

  Huffman, Mark D ^a   Prabhakaran, Dorairaj ^a  

^a CENTRE FOR CHRONIC DISEASE CONTROL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RAMIPRIL; RESERPINE; STREPTOCOCCUS VACCINE; THIAZIDE DIURETIC AGENT; TUBERCULOSTATIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG INDICATION; ECONOMIC DEVELOPMENT; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INCIDENCE; INDIA; ISCHEMIC HEART DISEASE; OBESITY; PATIENT PARTICIPATION; POPULATION DYNAMICS; PREVALENCE; PRIMARY PREVENTION; REHABILITATION CARE; REVIEW; RHEUMATIC HEART DISEASE; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SMOKING; SODIUM RESTRICTION; TUBERCULOSIS; REHABILITATION; RISK FACTOR;

HEART FAILURE; HUMANS; INCIDENCE; INDIA; PREVALENCE; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION; TERTIARY PREVENTION;

EID: 78650621004     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: A review of the literature. Int J Cardiol 2001;80:213-19.
2. World Health Organization. Global burden of disease-2004 update. Geneva: Switzerland; 2004.
3. Vakil RJ. A statistical study of 1281 cases of congestive cardiac failure or myocardial insufficiency in India. Indian Physician 1949;8:281-9.
4. Gupta PN, Valiathan MS, Balakrishnan KG, Kartha CC, Ghosh MK. Clinical course of endomyocardial fibrosis. Br Heart J 1989;62:450-4.
5. Achari V, Prakash S, Sinha AK, Thakur AK. Short-term mortality and complications in ST elevation myocardial infarction-the Heart Hospital experience. J Indian Med Assoc 2008;106:650-4.
6. Grover G, Dutta R, Gadpayle AK, Saha S. Changing patterns of cardiovascular risk factors and heart related sickness in relation with acute myocardial infarction in Delhi, India. J Indian Med Assoc 2009;107:636, 638, 640 passim.
7. Ramachandran K, Husain N, Maikhuri R, Seth S, Vij A, Kumar M, et al. Impact of a comprehensive telephone-based disease management programme on quality-of-life in patients with heart failure. Natl Med J India 2007;20:67-73.
8. National Commission on Population, Government of India. Available at http://populationcommission.nic.in/ (accessed on 3 March 2010).
9. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation 2002;106:3068-72.
10. Omran AR. The epidemiologic transition: A theory of the epidemiology of population change. Milbank Mem Fund Q. 1971;49:509-38.
11. Olshansky SJ, Ault AB. The fourth stage of the epidemiologic transition: The age of delayed degenerative diseases. Milbank Q 1986;64:355-91.
12. Yusuf S, Ounpuu S, Anand S. The global epidemic of atherosclerotic cardiovascular disease. Med Princ Pract 2002;11 Suppl 2:3-8.
13. Gaziano JM. Global burden of cardiovascular disease. In: Libby P, Bonow RO, Mann DL, Zipes DP (eds). Braunwald's heart disease: A textbook of cardiovascular medicine. 8th ed. New York:Saunders; 2007.
14. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008;94:16-26.
15. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
16. Fox KM; European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
17. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010; 121:e46-e215. Epub 2009 Dec 17.
18. World Health Organization. The WHO Global InfoBase. Geneva:Switzerland. Available at https://who.int/infobase (accessed on 3 March 2010).
19. HOT Study Group. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
20. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other bloodpressure- lowering drugs: Results of prospectively designed overviews of randomized trials. Lancet 2000; 356:1955-64.
21. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-13.
22. Reddy KS, Prabhakaran D, Shah P, Shah B. Differences in body mass index and waist: Hip ratios in North Indian rural and urban populations. Obes Rev 2002;3: 197-202.
23. Rodgers A, Ezzati M, Vander Hoorn S, Lopez AD, Lin RB, Murray CJ. Comparative risk assessment collaborating group distribution of major health risks: Findings from the global burden of disease study. PLoS Med 2004;1:e27.
24. Thakur JS, Negi PC, Ahluwalia SK, Vaidya NK. Epidemiological survey of rheumatic heart disease among school children in the Shimla hills of northern India: Prevalence and risk factors. J Epidemiol Community Health 1996;50:62-7.
25. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev 2002;3:CD002227.
26. Ali MK, Narayan KM, Mohan V. Innovative research for equitable diabetes care in India. Diabetes Res Clin Pract 2009; 86:155-167.
27. WHO. Coping with health care costs: Implications for the measurement of catastrophic expenditures and poverty: Health system performance assessment. Geneva: World Health Organization; 2003.
28. Prabhakaran D, Yusuf S, Mehta S, Pogue J, Avezum A, Budaj A, et al. Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: Results of the OASIS registry 1 and 2. Indian Heart J 2005; 57: 217-25.
29. Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, et al. Treatment and outcomes of acute coronary syndromes in India (CREATE): A prospective analysis of registry data. Lancet 2008;371:1435-42.
30. Commission on Social Determinants of Health (CSDH). Closing the gap in a generation: Health equity through action on the social determinants of health. Final Report of the Commission on Social Determinants of Health. Geneva:WHO; 2008.
31. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing committee to update the 2001 guidelines for the evaluation and management of heart failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-e235.
32. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010;362:590-9.
33. Tobacco Free Initiative. In: Reddy KS, Gupta PC. Report on tobacco control in India. New Delhi:Ministry of Health and Family Welfare, Government of India; 2008.
34. Gupta PC, Asma S (eds). Bidi smoking and public health. New Delhi: Ministry of Health and. Family Welfare, Government of India; 2008.
35. Chaloupka FJ, Hu TW, Warner KE, Jacobs R, Yurekli A. The taxation of tobacco products. In: Jha P, Chaloupka F (eds). Tobacco control in developing countries. Oxford:Oxford University Press, 2000:877-83.
36. Gaziano TA, Galea G, Reddy KS. Scaling up interventions for chronic disease prevention: The evidence. Lancet 2007;370:1939-46.
37. Oxman AD, Bjørndal A, Becerra-Posada F, Gibson M, Block MA, Haines A, et al. A framework for mandatory impact evaluation to ensure well informed public policy decisions. Lancet 2010;375:427-31.
38. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOPHypertension). Lancet 1991;338:1281-5.
39. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group. JAMA 1997;278:212-16.
40. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64.
41. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289:2560-72.
42. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-e479.
43. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary. BMJ 2004;328:634-40.
44. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249-54.
45. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681-9.
46. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998;339:1349-57.
47. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-91.
48. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACEinhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.
49. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385-90.
50. Antman EM. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non- ST segment elevation myocardial infarction: Appropriate interpretation of the guidelines. Am Heart J 2003;146 (4 Suppl):S18-S22.
51. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
52. Lindholm LH, Dahlöf B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH. LIFE study group. Effect of losartan on sudden cardiac death in people with diabetes: Data from the LIFE study. Lancet 2003;362:619-20.
53. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-72.
54. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
55. Karthikeyan G, Mayosi BM. Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa? Circulation 2009;120:709-13.
56. Rheumatic fever and rheumatic heart disease: Report of a WHO Expert Consultation, Geneva 29 October-1 November 2001. World Health Organ Tech Rep Ser 2004;923:1-122.
57. Nordet P, Lopez R, Dueñas A, Sarmiento L. Prevention and control of rheumatic fever and rheumatic heart disease: The Cuban experience (1986-1996-2002). Cardiovasc J Afr 2008;19:135-40.
58. Arguedas A, Mohs E. Prevention of rheumatic fever in Costa Rica. J Pediatr 1992;121:569-72.
59. Soudarssanane MB, Karthigeyan M, Mahalakshmy T, Sahai A, Srinivasan S, Subba Rao KS, et al. Rheumatic fever and rheumatic heart disease: Primary prevention is the cost effective option. Indian J Pediatr 2007;74:567-70.
60. Ntsekhe M, Wiysonge C, Volmink JA, Commerford PJ, Mayosi BM. Adjuvant corticosteroids for tuberculous pericarditis: Promising, but not proven. QJM 2003;96:593-9.
61. Investigation of the Management of Pericarditis in Africa (IMPI Africa). ClinicalTrials.gov identifier: NCT00810849. Available at http://clinicaltrials.gov/ct2/show/NCT00810849 (accessed on 23 August 2010).
62. Brilakis ES, Hernandez AF, Dai D, Peterson ED, Banerjee S, Fonarow GC, et al. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: Results from the Get With the Guidelines Program. Circulation 2009;120:560-7.
63. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: Results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE HF). Arch Intern Med 2007;167:1493-502.
64. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: Primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010;122:585-96.
65. Abegunde DO, Shengelia B, Luyten A, Cameron A, Celletti F, Nishtar S, et al. Can non-physician health-care workers assess and manage cardiovascular risk in primary care? Bull World Health Organ 2007;85:432-40.